Centerpoint Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Centerpoint Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	-$2K	–	644
2022 Q4	$2K	Hold	13	–	–	﹤0.01%	413
2022 Q3	$1K	Hold	13	–	–	﹤0.01%	366
2022 Q2	$1K	Hold	13	–	–	﹤0.01%	373
2022 Q1	$1K	Hold	13	–	–	﹤0.01%	383
2021 Q4	$1K	Buy	+13	New	+$1.11K	﹤0.01%	410

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Centerpoint Advisors's SRPT Position: Q1 2023 in Review

Centerpoint Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 13 shares — an estimated $2K sold.

Centerpoint Advisors first reported a position in SRPT in Q4 2021 and held it in 5 quarters. The position peaked at $2K in Q4 2022. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

Centerpoint Advisors reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
Centerpoint Advisors sold 13 Sarepta Therapeutics shares in Q1 2023, an estimated $2K.
Centerpoint Advisors first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 5 quarters.
Centerpoint Advisors's Sarepta Therapeutics position peaked at $2K in Q4 2022.
425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Centerpoint Advisors's 13F filing for Q1 2023, filed 3 May 2023.